These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37851052)

  • 1. Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade.
    Tabachnick-Cherny S; Pulliam T; Rodriguez HJ; Fan X; Hippe DS; Jones DC; Moshiri AS; Smythe KS; Kulikauskas RM; Zaba LC; Paulson KG; Nghiem P
    Clin Cancer Res; 2024 Mar; 30(6):1189-1199. PubMed ID: 37851052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers.
    Afanasiev OK; Yelistratova L; Miller N; Nagase K; Paulson K; Iyer JG; Ibrani D; Koelle DM; Nghiem P
    Clin Cancer Res; 2013 Oct; 19(19):5351-60. PubMed ID: 23922299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Merkel cell carcinomas infiltrated with CD33
    Kervarrec T; Gaboriaud P; Berthon P; Zaragoza J; Schrama D; Houben R; Le Corre Y; Hainaut-Wierzbicka E; Aubin F; Bens G; Domenech J; Guyétant S; Touzé A; Samimi M
    J Am Acad Dermatol; 2018 May; 78(5):973-982.e8. PubMed ID: 29273486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.
    Church C; Pulliam T; Longino N; Park SY; Smythe KS; Makarov V; Riaz N; Jing L; Amezquita R; Campbell JS; Gottardo R; Pierce RH; Choi J; Chan TA; Koelle DM; Nghiem P
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36252564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
    Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
    Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses.
    Pulliam T; Jani S; Goff PH; Bhakuni R; Tabachnick-Cherny S; Smythe K; Seaton BW; Tachiki L; Kulikauskas R; Church C; Koelle DM; Nghiem P; Bhatia S
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39401968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.
    Miller NJ; Church CD; Fling SP; Kulikauskas R; Ramchurren N; Shinohara MM; Kluger HM; Bhatia S; Lundgren L; Cheever MA; Topalian SL; Nghiem P
    J Immunother Cancer; 2018 Nov; 6(1):131. PubMed ID: 30482247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into anti-tumor immunity
    Jani S; Church CD; Nghiem P
    Front Immunol; 2023; 14():1172913. PubMed ID: 37287968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.
    Feldmeyer L; Hudgens CW; Ray-Lyons G; Nagarajan P; Aung PP; Curry JL; Torres-Cabala CA; Mino B; Rodriguez-Canales J; Reuben A; Chen PL; Ko JS; Billings SD; Bassett RL; Wistuba II; Cooper ZA; Prieto VG; Wargo JA; Tetzlaff MT
    Clin Cancer Res; 2016 Nov; 22(22):5553-5563. PubMed ID: 27166398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
    Spassova I; Ugurel S; Kubat L; Zimmer L; Terheyden P; Mohr A; Björn Andtback H; Villabona L; Leiter U; Eigentler T; Loquai C; Hassel JC; Gambichler T; Haferkamp S; Mohr P; Pfoehler C; Heinzerling L; Gutzmer R; Utikal JS; Horny K; Schildhaus HU; Habermann D; Hoffmann D; Schadendorf D; Becker JC
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses.
    Dowlatshahi M; Huang V; Gehad AE; Jiang Y; Calarese A; Teague JE; Dorosario AA; Cheng J; Nghiem P; Schanbacher CF; Thakuria M; Schmults CD; Wang LC; Clark RA
    J Invest Dermatol; 2013 Jul; 133(7):1879-89. PubMed ID: 23419694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma.
    Pulliam T; Jani S; Jing L; Ryu H; Jojic A; Shasha C; Zhang J; Kulikauskas R; Church C; Garnett-Benson C; Gooley T; Chapuis A; Paulson K; Smith KN; Pardoll DM; Newell EW; Koelle DM; Topalian SL; Nghiem P
    Cell Rep Med; 2024 Feb; 5(2):101412. PubMed ID: 38340723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.
    Colunga A; Pulliam T; Nghiem P
    Clin Cancer Res; 2018 May; 24(9):2035-2043. PubMed ID: 29217527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling.
    Martins C; Rasbach E; Heppt MV; Singh P; Kulcsar Z; Holzgruber J; Chakraborty A; Mucciarone K; Kleffel S; Brandenburg A; Hoetzenecker W; Rahbari NN; DeCaprio JA; Thakuria M; Murphy GF; Ramsey MR; Posch C; Barthel SR; Schatton T
    Sci Adv; 2024 Jan; 10(3):eadi2012. PubMed ID: 38241371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
    Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
    Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T antigen-specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma.
    Hansen UK; Church CD; Carnaz Simões AM; Frej MS; Bentzen AK; Tvingsholm SA; Becker JC; Fling SP; Ramchurren N; Topalian SL; Nghiem PT; Hadrup SR
    J Clin Invest; 2024 Jan; 134(8):. PubMed ID: 38618958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
    Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
    Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy.
    Reinstein ZZ; Zhang Y; Ospina OE; Nichols MD; Chu VA; Pulido AM; Prieto K; Nguyen JV; Yin R; Moran Segura C; Usman A; Sell B; Ng S; de la Iglesia JV; Chandra S; Sosman JA; Cho RJ; Cheng JB; Ivanova E; Koralov SB; Slebos RJC; Chung CH; Khushalani NI; Messina JL; Sarnaik AA; Zager JS; Sondak VK; Vaske C; Kim S; Brohl AS; Mi X; Pierce BG; Wang X; Fridley BL; Tsai KY; Choi J
    Cancer Discov; 2024 Sep; 14(9):1631-1652. PubMed ID: 39058036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merkel cell carcinoma expresses the immunoregulatory ligand CD200 and induces immunosuppressive macrophages and regulatory T cells.
    Gaiser MR; Weis CA; Gaiser T; Jiang H; Buder-Bakhaya K; Herpel E; Warth A; Xiao Y; Miao L; Brownell I
    Oncoimmunology; 2018; 7(5):e1426517. PubMed ID: 29721394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
    Gehrcken L; Sauerer T; Schaft N; Dörrie J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.